Clinical ResultsAlpha Tau Medical reported positive interim results for the first eight patients receiving a combination of Alpha DaRT and Keytruda for the treatment of recurrent unresectable or metastatic head and neck squamous cell carcinoma, with a systemic objective response rate of 75%.
Clinical TrialsThe company is slated to start patient enrollment for a U.S. pilot study of Alpha DaRT together with first-line chemotherapy in patients with newly diagnosed pancreatic cancer.
Strategic InvestmentA $36.9M strategic investment from Oramed validates Alpha Tau’s novel technology and its potential in oncology therapeutics.